Preanalytical Pitfalls in Untargeted Plasma Nuclear Magnetic Resonance Metabolomics of Endocrine Hypertension.
confounders
metabolomics
multicenter
plasma NMR
preanalytical conditions
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
24 Jul 2022
24 Jul 2022
Historique:
received:
30
05
2022
revised:
17
06
2022
accepted:
11
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Despite considerable morbidity and mortality, numerous cases of endocrine hypertension (EHT) forms, including primary aldosteronism (PA), pheochromocytoma and functional paraganglioma (PPGL), and Cushing's syndrome (CS), remain undetected. We aimed to establish signatures for the different forms of EHT, investigate potentially confounding effects and establish unbiased disease biomarkers. Plasma samples were obtained from 13 biobanks across seven countries and analyzed using untargeted NMR metabolomics. We compared unstratified samples of 106 PHT patients to 231 EHT patients, including 104 PA, 94 PPGL and 33 CS patients. Spectra were subjected to a multivariate statistical comparison of PHT to EHT forms and the associated signatures were obtained. Three approaches were applied to investigate and correct confounding effects. Though we found signatures that could separate PHT from EHT forms, there were also key similarities with the signatures of sample center of origin and sample age. The study design restricted the applicability of the corrections employed. With the samples that were available, no biomarkers for PHT vs. EHT could be identified. The complexity of the confounding effects, evidenced by their robustness to correction approaches, highlighted the need for a consensus on how to deal with variabilities probably attributed to preanalytical factors in retrospective, multicenter metabolomics studies.
Identifiants
pubmed: 35893246
pii: metabo12080679
doi: 10.3390/metabo12080679
pmc: PMC9394285
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Union
ID : 633983
Références
Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50
pubmed: 29129575
Stat Appl Genet Mol Biol. 2008;7(1):Article 35
pubmed: 19049491
Sci Rep. 2020 May 5;10(1):7517
pubmed: 32371946
J Proteome Res. 2018 Apr 6;17(4):1586-1595
pubmed: 29457906
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
Transl Res. 2016 Dec;178:25-37.e7
pubmed: 27477079
High Blood Press Cardiovasc Prev. 2020 Dec;27(6):547-560
pubmed: 33159664
Clin Chem. 1994 Jul;40(7 Pt 1):1245-50
pubmed: 8013094
Anal Chem. 2006 Jul 1;78(13):4281-90
pubmed: 16808434
Metabolites. 2019 May 17;9(5):
pubmed: 31108909
Bioinformatics. 2001 Jun;17(6):520-5
pubmed: 11395428
Pharm Stat. 2011 Jan-Feb;10(1):50-9
pubmed: 20112277
Electrophoresis. 2015 Sep;36(18):2148-2155
pubmed: 25820922
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Int J Mol Sci. 2016 Dec 05;17(12):
pubmed: 27929400
Nat Protoc. 2016 Feb;12(2):310–328
pubmed: 28079878
J Hypertens. 2020 Aug;38(8):1443-1456
pubmed: 32412940
Kidney Int Rep. 2018 Oct 17;4(2):321-333
pubmed: 30775629
J Appl Lab Med. 2020 Jan 1;5(1):83-90
pubmed: 31811074
Metabolomics. 2007 Sep;3(3):211-221
pubmed: 24039616
BMC Bioinformatics. 2011 Jun 22;12:253
pubmed: 21693065
Anal Chim Acta. 2015 Oct 29;899:1-12
pubmed: 26547490
J Biosci Bioeng. 2018 May;125(5):613-618
pubmed: 29258730
PLoS Comput Biol. 2018 Mar 1;14(3):e1006018
pubmed: 29494588
J Clin Endocrinol Metab. 2011 Mar;96(3):632-42
pubmed: 21193542
Anal Chem. 2006 Jul 1;78(13):4307-18
pubmed: 16808437
J Proteome Res. 2019 Jun 7;18(6):2411-2421
pubmed: 31074987
Anal Chem. 2021 Feb 16;93(6):3233-3240
pubmed: 33538164
Circ Cardiovasc Genet. 2010 Apr;3(2):207-14
pubmed: 20173117
High Blood Press Cardiovasc Prev. 2016 Sep;23(3):209-15
pubmed: 27160717
J Hypertens. 2019 Jun;37(6):1157-1166
pubmed: 30801385
Bioinformatics. 2017 Nov 15;33(22):3567-3574
pubmed: 29036400
Sci Rep. 2017 May 19;7(1):2153
pubmed: 28526818
J Proteome Res. 2018 Jan 5;17(1):203-211
pubmed: 29064256
Nat Med. 2002 Dec;8(12):1439-44
pubmed: 12447357
PLoS One. 2014 Feb 24;9(2):e89728
pubmed: 24586991
Metabolomics. 2010 Mar;6(1):119-128
pubmed: 20339442
J Clin Endocrinol Metab. 2013 Mar;98(3):1100-6
pubmed: 23408574
Nat Biotechnol. 2008 Feb;26(2):162-4
pubmed: 18259166
Gland Surg. 2020 Feb;9(1):43-58
pubmed: 32206598
J Biomol NMR. 2011 Apr;49(3-4):231-43
pubmed: 21380509
Nucleic Acids Res. 2018 Jan 4;46(D1):D608-D617
pubmed: 29140435
J Hypertens. 2020 Oct;38(10):1919-1928
pubmed: 32890264
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
Anal Chem. 2006 Jul 1;78(13):4430-42
pubmed: 16808451
Endocrine. 2022 Jan;75(1):254-265
pubmed: 34536194
Int J Endocrinol. 2017;2017:1547358
pubmed: 28819359
Anal Chem. 2013 Mar 5;85(5):2606-10
pubmed: 23387999
Nat Med. 2006 Jun;12(6):705-10
pubmed: 16732278
Metabolites. 2019 Apr 03;9(4):
pubmed: 30987180
J Inherit Metab Dis. 2018 May;41(3):337-353
pubmed: 29453510
Pharm Stat. 2014 Mar-Apr;13(2):145-52
pubmed: 24523155
J Clin Endocrinol Metab. 2021 Mar 25;106(4):1111-1128
pubmed: 33382876
Nat Rev Cancer. 2005 Feb;5(2):142-9
pubmed: 15685197
Bioinformatics. 2005 Jul 1;21(13):3043-8
pubmed: 15890747
Eur Heart J. 2012 Sep;33(18):2307-16
pubmed: 22450427
BMC Bioinformatics. 2007 Jul 02;8:234
pubmed: 17605789
Bioinformatics. 2012 Aug 1;28(15):2088-90
pubmed: 22635605
Clin Chim Acta. 2017 Mar;466:105-111
pubmed: 28069401
Anal Chim Acta. 2015 Jan 7;854:95-105
pubmed: 25479872
Metabolomics. 2012 Jun;8(Suppl 1):3-16
pubmed: 22593721
Lancet Diabetes Endocrinol. 2014 Jan;2(1):65-75
pubmed: 24622670
Metabolomics. 2020 May 1;16(5):64
pubmed: 32358672
Hypertension. 2012 Sep;60(3):618-24
pubmed: 22824982
Analyst. 2014 Mar 7;139(5):1168-77
pubmed: 24443722
Clin Chem. 2014 Feb;60(2):399-412
pubmed: 24305685
Metabolomics. 2020 May 25;16(6):68
pubmed: 32451742